SCHEMBL18015115

SCHEMBL18015115

CC(C)(C)OC(=O)N1CCC[C@H]1COC(F)F

nearest known ligand 0.45

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALOX5AP P20292 1/20 0.45
FEN1 P39748 1/20 0.45
HSD17B10 Q99714 1/20 0.43
ALDH1A1 P00352 2/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
TSHR P16473 1/20 0.40
PDE8B O95263 1/20 0.39
OPRD1 P41143 1/20 0.39
ATM Q13315 2/20 0.39
NPC1 O15118 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18015118 1.00 ALOX5AP (0.45) ALOX5APFEN1HSD17B10ALDH1A1MEN1
SCHEMBL18015133 1.00 ALOX5AP (0.45) ALOX5APFEN1HSD17B10ALDH1A1MEN1
SCHEMBL18015128 0.96 PDE8B (0.43) ALOX5APFEN1HSD17B10ALDH1A1MEN1
SCHEMBL19779316 0.96 PDE8B (0.43) ALOX5APFEN1HSD17B10ALDH1A1MEN1
SCHEMBL18015127 0.96 PDE8B (0.43) ALOX5APFEN1HSD17B10ALDH1A1MEN1
SCHEMBL18015116 0.92 ALOX5AP (0.38) ALOX5APFEN1HSD17B10ALDH1A1MEN1
SCHEMBL18015124 0.88 ATM (0.43) ALOX5APFEN1HSD17B10ALDH1A1MEN1
SCHEMBL18015134 0.88 ATM (0.43) ALOX5APFEN1HSD17B10ALDH1A1MEN1
SCHEMBL18015119 0.88 ATM (0.43) ALOX5APFEN1HSD17B10ALDH1A1MEN1
SCHEMBL24922942 0.87 HSD17B10 (0.44) ALOX5APFEN1HSD17B10ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113072542-B ROR gamma t inhibitor and preparation method and application thereof 广东东阳光药业股份有限公司 2024-04-05 CN disclosed
US-20230121086-A1 RORgT INHIBITOR, PREPARATION METHOD THEREOF AND USE THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2023-04-20 US disclosed
EP-4089080-A1 RORyT INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF Sunshine Lake Pharma Co., Ltd. (CN) 2022-11-16 EP disclosed
WO-2021139595-A1 RORγT INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF 东莞市东阳光新药研发有限公司 2021-07-15 WO disclosed
CN-113072542-A ROR gamma t inhibitor and preparation method and application thereof 广东东阳光药业有限公司 2021-07-06 CN disclosed
US-20180016227-A1 PROCESS FOR THE SYNTHESIS OF DIFLUOROMETHYL ETHER-BASED COMPOUNDS TRILLIUM THERAPEUTICS INC. (CA) 2018-01-18 US disclosed
WO-2016123707-A1 PROCESS FOR THE SYNTHESIS OF DIFLUOROMETHYL ETHER-BASED COMPOUNDS TRILLIUM THERAPEUTICS INC. (CA) 2016-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180016227-A1 PROCESS FOR THE SYNTHESIS OF DIFLUOROMETHYL ETHER-BASED COMPOUNDS CYP2F1, CYP2E1, PAH ALOX5AP 1273/4885FEN1 4052/4885HSD17B10 193/4885
US-20230121086-A1 RORgT INHIBITOR, PREPARATION METHOD THEREOF AND USE THEREOF RORC, RORB, RORA ALOX5AP 1378/4885FEN1 4574/4885HSD17B10 1179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.